AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Atopic Dermatitis and The Skin Barrier

Description

The presentation discusses the role of the skin barrier in atopic dermatitis (AD) and introduces the idea of preclinical atopic dermatitis in infants. The speaker highlights the complex interplay between skin barrier dysfunction, immune responses, and the microbiome, emphasizing how skin barrier integrity is crucial for preventing AD. Key components like filaggrin, a protein essential for skin barrier function, are explored, along with the implications of its mutations on atopic disease susceptibility. The early transition from the sterile womb to the external environment puts immense stress on the skin barrier, which adapts with adaptive mechanisms. Studies show that infants destined to develop AD have pre-existing changes in skin composition, suggesting a need for early intervention. Current evidence on barrier prevention strategies for AD remains mixed, with some studies indicating potential benefits, particularly for high-risk infants. A recent randomized trial found that early application of emollients reduced the incidence of AD in genetically predisposed infants. The discussion concludes with the importance of understanding skin barrier dysfunction and the potential for pharmacological interventions, particularly targeting immune responses to aid barrier restoration and management of AD.

View more

Conclusions

  • Barrier dysfunction is a central characteristic of atopic dermatitis (AD).
  • Genetic factors, the microbiome, and environmental influences contribute to the development of barrier dysfunction in AD.
  • Preclinical signs of atopic dermatitis can be identified in infants before the onset of clinical symptoms through specific biomarker profiles.
  • Early life alterations in skin barrier function, including low natural moisturizing factors, can predict later development of AD.
  • Daily emollient use within the first few weeks of life may significantly reduce the incidence of AD in high-risk infants.
  • Filaggrin mutations are linked to increased severity and persistence of atopic dermatitis and other allergic conditions.
  • S. aureus colonization in the skin is associated with barrier dysfunction and can exacerbate atopic dermatitis symptoms.
  • Current pharmacological treatments can potentially improve skin barrier function by modulating inflammatory responses.
  • The interplay between skin barrier integrity and type 2 immune responses is vital in the pathogenesis of atopic dermatitis.
  • C. Drislane, A.D. Irvine, Ann Allergy Asthma Immunol 124 (2020).
  • Palmer CNA, et al. Nat Genet 2006; 38:441-6.
  • Kelleher, MM, Cro, S, Van Vogt, E, et al. Clin Exp Allergy. 2021; 51: 402-418.
  • Kennedy et al. J Allergy Clin Immunol. 2017;139: 166-72.
  • Bunikowski R et al. Pediatr Allergy Immunol. 2003;14:55-59.
  • Clarysse et al, J Eur Acad Dermatol Venereol, 2019.
  • Ní Chaoimh et al. Allergy 2023;78:984-994.
  • Harding 1986.